Online First

Study on Effects of Jinhua Qinggan Granules in the Treatment of COVID-19 based on Network Pharmacology

LIN Jia-rong1 ZHENG Wei-wu1 ZENG Gui-xing2 LIN Qi-zhan1

(1.The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China 510120)
(2.Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China 510405)

【Abstract】 Objective To explore the mechanism of Jinhua Qinggan Granules in treating COVID-19. Methods According to ADME characteristics of drugs, the active compounds and targets of Jinhua Qinggan Granules were screened by TCMSP platform. The component target network was constructed. The related targets of COVID-19 were retrieved based on GeneCards database. The protein-protein interaction (PPI) network was constructed by STRING database and the key targets were screened by Cytoscape software. The obtained target information was analyzed using DAVID database to analyze biological processes and pathway enrichment. Results 263 targets of Jinhua Qinggan Granules and 346 COVID-19 related target genes were screened out, and the mapping resulted in 49 common genes. The important gene targets were IL6, IL1β, CXCL8, CCL2, IL2, IL4, ICAM1, IL10, IFNG, and IL1 A. The GO analysis results showed that the biological processes mainly included cytokine activity, MAP kinase activity, chemokine activity, inflammatory response, and immune response. KEGG pathway analysis showed that Jinhua Qinggan Granules’ signaling pathways for the treatment of COVID-19 mainly included TNF signaling pathway, influenza A, HIF-1 signaling pathway, NOD-like receptor signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, MAPK signaling pathway, and T cell receptor signaling pathway. Conclusion Jinhua Qinggan Granules exert the therapeutic effects on COVID-19 by acting on multiple targets and multiple pathways to regulate the immunity and reduce inflammation, but its mechanism still needs to be confirmed by experiments.

【Keywords】 Jinhua Qinggan Granules; COVID-19; Network pharmacology; Mechanism of action;

【DOI】

【Funds】 Infrastructure Program of Workshop to Inherit Academic Experience of Zhang Qi from Guangdong Provincial Hospital of Chinese Medicine (E43712)

Download this article

    References

    [1] Ge H Y. 张琪辨治肺系疾病经验 [J]. Shandong Journal of Traditional Chinese Medicine, 2003 (7): 437–438 (in Chinese).

    [2] Li G Q, Zhao J, Tu Z T, et al. Treating influenza patients of wind-heat affecting fei syndrome by jinhua qinggan granule: a double-blinded randomized control trial [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2013, 33 (12): 1631–1635 (in Chinese).

    [3 Li G Q, Zhao J, Tu Z T, et al. Treating influenza patients of wind-heat affecting fei syndrome by jinhua qinggan granule: a double-blinded randomized control trial [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2013, 33 (12): 1631–1635 (in Chinese).

    [4] Huo H. 麻杏石甘汤合银翘散加减治疗小儿风热闭肺型肺炎喘嗽效果观察 [J]. Inner Mongolia Medical Journal, 2019, 51 (4): 481–482 (in Chinese).

    [5 Chai S Q, Yu S F, Zhu H . Effects of maxing shigan decoction on pneumonia model mice and its effect on cd137 level of costimulatory molecule [J]. World Chinese Medicine, 2019, 14 (2): 345–348 (in Chinese).

    [6] Wang J, Feng X H, Guo L N, et al. 银翘散对流感病毒感染性重症肺炎小鼠肺组织的修复机制研究 [J]. Shaanxi Journal of Traditional Chinese Medicine, 2020, 41 (2): 156–159 (in Chinese).

    [7] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. JAMA, 2020.

    [8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. LANCET, 2020, 395 (10223): 497–506.

    [9] Wang Y L, Wang F, Geng J. 细胞因子与细胞因子风暴 [J]. Tianjin Medical Journal, 2020: 1–6 (in Chinese).

    [10] Chen H, Wang F, Zhang P, et al. Management of cytokine release syndrome related to CAR-T cell therapy [J]. Front Med, 2019, 13 (5): 610–617.

    [11] Nencioni L, De Chiara G, Sgarbanti R, et al. Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication [J]. J BIOL CHEM, 2009, 284 (23): 16004–16015.

    [12] Meineke R, Rimmelzwaan G F, Elbahesh H. Influenza Virus Infections and Cellular Kinases [J]. Viruses, 2019, 11 (2).

    [13] Weinmann A S. Regulatory mechanisms that control T-follicular helper and T-helper 1 cell flexibility [J]. IMMUNOL CELL BIOL, 2014, 92 (1): 34–39.

    [14] Guo X, Zhu Z, Zhang W, et al. Nuclear translocation of HIF-1alpha induced by influenza A (H1N1) infection is critical to the production of proinflammatory cytokines [J]. Emerg Microbes Infect, 2017, 6 (5): e39.

    [15] Qiu Y, Chen C, Zhang J, et al. VEGF attenuates lung injury by inducing homing of CD133 (+) progenitors via VEGFR1 [J]. Biochem Biophys Res Commun, 2019, 511 (3): 650–657.

    [16] Wiese K M, Coates BM, Ridge KM. The Role of Nucleotide-Binding Oligomerization Domain-Like Receptors in Pulmonary Infection. Am J Respir Cell Mol Biol, 2017, 57 (2): 151–161.

    [17] Leiva-Juarez MM, Kirkpatrick CT, Gilbert B E, et al. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir [J]. EUR J PHARMACOL, 2018, 818: 191–197.

This Article

ISSN:1001-4454

CN: 44-1286/R

Vol , No. 05, Pages

Downloads:0

Share
Article Outline

Abstract

  • 1 Materials and methods
  • 2 Results
  • 3 Discussion
  • 4 Conclusion
  • References